Biotech is where capital meets one of the most durable structural tailwinds in markets: an ageing global population and the scientific breakthroughs to address it. Logan's clients access biotech selectively — through specialist managers, diversified vehicles, and direct relationships sourced via Boston Global Group's network, which includes the FSHD Global Research Foundation founded by BGW Chairman Bill Moss AO.
Equity and venture exposure to companies developing therapeutics, diagnostics, genomics and platform technologies in human health. The opportunity set spans listed biotech, late-stage private companies preparing for trial readouts or commercial launch, and earlier-stage ventures backing breakthrough science.
Therapeutic markets are large, durable and growing. Successful biotech exits — clinical milestones, strategic acquisitions, IPOs — can return multiples of capital in a single position. Logan's role is to size biotech as a measured allocation within a broader portfolio, not a concentrated bet, and to select managers with the science depth and patience to underwrite the cycle.
Through specialist healthcare-focused VC and growth funds on BGW's APL, diversified late-stage private-shares strategies that include biotech alongside other innovation themes, and direct allocations sourced through Boston Global Group's relationships in the medical-research community.
Biotech is high risk by nature — binary clinical and regulatory outcomes, long timelines, and significant single-company concentration risk. Approved exposure is risk capital only, sized to the client's overall portfolio, and held in diversified vehicles wherever possible. Returns are indicative; capital is at risk.
Logan will tell you straight — whether it earns its place, how much would make sense, and how it fits alongside what you already hold.
Book a Consultation